FGEN FibroGen Inc Future Profit

FibroGen, Inc. (FGEN) invests in tissue regeneration and small molecules. The forward yield metric visualizes these expectations, where the value of reflects this status. Monopoly pricing power for anemia drugs supports revenue until the entry of generics. The company is currently undergoing rigorous cost optimization and seeking partners to stabilize liquidity following a series of failed trials.

fibrogen.com (FGEN): Expected Net Profit from 07/04/2022 to 11/15/2026

FibroGen Corp - analytical breakdowns and key metrics (FGEN)

- share price and consensus valuation forecast:

Stock Price fibrogen.com|FGEN - Analyst Consensus Forecast

- market capitalization data:

Market Valuation FibroGen Corp|FGEN - Value Adjusted for Debt and Cash

- book capitalization information:

Net Assets per Single Share FibroGen|FGEN - Total Stockholders' Equity|Market Cap to Net Assets Ratio fibrogen.com|FGEN - Aggregate Business Assets

- company total debt and liquidity indicators:

- net income and valuation ratios data:

FGEN - Net Financial Result|Projected Future Earnings FibroGen, Inc.|FGEN - Price to Earnings Ratio|Future Price to Earnings FibroGen Corp|FGEN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen|FGEN - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) FibroGen|FGEN - Net earnings per share for the trailing year|Quarterly EPS earnings growth fibrogen.com|FGEN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year FibroGen, Inc.

- total revenue and sales volume data:

FGEN - Company Sales Volume|Company Future Sales Volume FibroGen|FGEN - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple FibroGen Corporation|FGEN - Annual Revenue Growth (Last Twelve Months)

Fundamental company analysis:FGEN, FibroGen

Assessing the financial stability of FibroGen, Inc. (FGEN) requires an analysis of long-term profitability. This indicator measures expected operating returns based on current market conditions and revenue forecasts. By analyzing the company's expected financial results, an investor can distinguish real growth from a speculative spike. For the biotechnology sector, this metric reflects the effectiveness of commercializing anti-fibrosis drugs through global partners. The profit forecast confirms the viability of the issuer's business model.

Competitor analysis for FibroGen, Inc.